Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.MedAssets to acquire Accuro Healthcare Solutions
Under the terms of the agreement, MedAssets will pay approximately $207 million in cash and 8.85 million shares of MedAssets common stock, plus a deferred payment of $20
Under the terms of the agreement, MedAssets will pay approximately $207 million in cash and 8.85 million shares of MedAssets common stock, plus a deferred payment of $20
This new partnership combines Octagon’s expertise in electronic submissions with Premier Research’s extensive clinical expertise across a wide array of therapeutic areas. The partnership enables Premier Research to
This is the second improvement to the production process approved by the FDA this year. The combination of these improvements is expected to increase batch yields of the
Mr Bihl succeeds Ross Longhini, who has served as interim CEO since January, 2008. Mr Longhini will remain in his role as executive vice president and COO. Mr
CGEN-438 is a novel splice variant peptide of delta-like protein 3 precursor (DLL3). Importantly, the Compugen discovered biomarker is a peptide that is secreted from the cell into
This patent is part of Redpoint Bio’s founding intellectual property portfolio, originally developed in the laboratory of Robert Margolskee, and exclusively licensed from the Mount Sinai School of
Jonas Ohlsson, former CEO at Mentice, has extensive experience of the biotech industry and has held executive positions at PE Applied Biosystems, Kovalent and AstraZeneca. Significantly, Mr Ohlsson
Under the agreement, Digirad and the Medical Center will offer their respective services and expertise to primary-care physicians in the Chicago area who are seeking to expand their
According to the company, the expansion into the US will ensure that appropriate resources are available to support its numerous planned clinical programs as well as subsequent US
The centers will be administering the FDA approved iCAT treatment for diabetes and related wound care for Type 1 and Type 2 diabetes patients. These are the first